Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Human medicine
Name of medicinal product: RYEQO
Active substances:
Relugolix+Estradiol+Norethisterone
Estonian, English, Latin
ATC code: H01CC54
Dosage form: film-coated tablet
Strength: 40mg+1mg+0,5mg
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Labelling:  
Indication: Ryeqo is indicated in adult women of reproductive age for: - treatment of moderate to severe symptoms of uterine fibroids, - symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1).
Safety features: Yes
: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Patients and healthcare professionals are asked to report any suspected adverse reactions to State Agency of Medicines.State Agency of Medicines
Marketing authorization holder: Gedeon Richter Plc. 
Marketing authorization number: EU/1/21/1565 
Marketing authorization issued on: July 16, 2021 
Marketing authorization expires on: July 20, 2026 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1858103  RYEQO  film-coated tablet  40mg +1mg +0,5mg 28TK  Prescription  90% 100% 75%    17.06.2024     
3052000  RYEQO  film-coated tablet  40mg +1mg +0,5mg 84TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere